Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Tarkowski

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Frontiers in Immunology|April 4, 2022
Definition of the Immune Parameters Related to COVID-19 SeveritySarah Birindelli, Maciej S Tarkowski, Marcello Gallucci, et al.
Frontiers in Immunology|June 9, 2023
Corrigendum: Definition of the immune parameters related to COVID-19 severitySarah Birindelli, Maciej S Tarkowski, Marcello Gallucci, et al.
International Journal of Cancer|September 3, 2022
Immunogenicity of two doses of BNT162b2 and mRNA-1273 vaccines for solid cancer patients on treatment with or without a previous SARS-CoV-2 infectionNicla La Verde, Agostino Riva, Maria Silvia Cona, et al.
Cancer Medicine|April 28, 2023
Clinical efficacy of the first two doses of anti-SARS-CoV-2 mRNA vaccines in solid cancer patientsMaria Silvia Cona, Agostino Riva, Davide Dalu, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Frontiers in Immunology|April 4, 2022
Definition of the Immune Parameters Related to COVID-19 SeveritySarah Birindelli, Maciej S Tarkowski, Marcello Gallucci, et al.
Frontiers in Immunology|June 9, 2023
Corrigendum: Definition of the immune parameters related to COVID-19 severitySarah Birindelli, Maciej S Tarkowski, Marcello Gallucci, et al.
International Journal of Cancer|September 3, 2022
Immunogenicity of two doses of BNT162b2 and mRNA-1273 vaccines for solid cancer patients on treatment with or without a previous SARS-CoV-2 infectionNicla La Verde, Agostino Riva, Maria Silvia Cona, et al.
Cancer Medicine|April 28, 2023
Clinical efficacy of the first two doses of anti-SARS-CoV-2 mRNA vaccines in solid cancer patientsMaria Silvia Cona, Agostino Riva, Davide Dalu, et al.
Pageof 3